Global Industry Analysts, Inc., Feb 2011, Pages: 293
Cholesterol & OtherCardiovascularTesting - Global Strategic Business Report This report analyzes the worldwide markets for Cholesterol & OtherCardiovascularTesting in Million Units
Decision Resources, Inc., Dec 2007, Pages: 24
Preventing Cardiovascular Events: Will HDL Therapeutics Change the Treatment Paradigm? Introduction
The notion that raising HDL cholesterol levels can reduce the risk of coronary heart disease
Nicholas Hall Group, March 2010, Pages: 242
Overview - ovulation tests
Analysis of key markets
Innovations
Overview - other family planning diagnostics
Prospects for family planning diagnostics
Overview - blood pressure monitors
Analysis of key
John Wiley and Sons Ltd, Jan 2008, Pages: 376
Evidence-Based Medical Monitoring Monitoring is a major component of management of chronic diseases such as diabetes, cardiovascular disease, arthritis and depression. Yet poor monitoring means
Espicom Business Intelligence Ltd, April 2008, Pages: 314
into leading cardiovascular markets and products.
Cholesterol and Triglycerides
The global market for drugs used in the management of cholesterol is currently valued at around US$34 billion. Sales
Decision Resources, Inc., Dec 2005, Pages: 20
.
- Physicians in the United States identify controlling hypertension and elevated low-density lipoprotein (LDL) cholesterol as top clinical
priorities owing to the well-characterized cardiovascular risk
Knowledge Press, March 2004, Pages: 412
cholesterol levels remain a leading cause for atherosclerosis and othercardiovascular diseases, despite the multitude of available therapeutics.
In order to develop new pharmaceutical approaches
Harvard Health Publications/Staywell, Jan 2011, Pages: 48
blood pressure has no symptoms or warning signs. But when elevated blood pressure is accompanied by abnormal cholesterol and blood sugar levels, the damage to your arteries, kidneys, and heart accelerates
Informa Healthcare, Nov 1999, Pages: 352
of homocysteine and lipoprotein(a) and other recently identified CHD risk factors
- reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol
- and more
